Experimental medical treatments: who should decide coverage?
نویسنده
چکیده
Imagine you or your wife, your sister, your mother, your aunt, or your best friend, has just been diagnosed with breast cancer. Treatment is expensive. What if you or your loved one does not have medical insurance? Worse yet, what if you or your loved one has medical insurance, but it does not cover the treatment you need to survive? What are you going to do? Can you pay for the treatment out of pocket? What if it costs anywhere from $100,000-$300,000? If you do not have that kind of money sitting in the bank, can you raise the money? Will friends and family and the community donate their hard earned dollars to save a life? In the case of Nelene Fox, her family and community did just that.1 Unfortunately, the efforts of family and community were too late. By the time Nelene raised enough money to afford the High Dose Chemotherapy and Bone Marrow Transplant (HDC-ABMT) her doctor recommended, the cancer had advanced and her body had deteriorated to such a degree that the procedure could not help her.' Nelene Fox had health insurance coverage through her employer, but was denied coverage for the treatment by her health maintenance organization, HealthNet, because HealthNet deemed the coverage to be experimental. What caused the death of Nelene Fox: the cancer or the inability to get the treatment that she so desperately needed when she needed
منابع مشابه
Medical necessity: do we need it?
The term medical necessity has been mainly a placeholder in insurance plans for over thirty years. More recently, the national health care reform debate and litigation over denials of costly experimental treatments have broken the term out into open discussion about what a necessary service is and who should decide if it is covered. This paper summarizes the history of the term and its evolutio...
متن کاملImproving the Quality and Efficiency of the Medicare Program Through Coverage Policy
In the face of large and growing budget deficits, finding ways to bend the health care cost curve and improve the efficiency of the Medicare program has been a central focus of budget policy. Medicare spends more than $500 billion annually for more than 46 million senior and disabled beneficiaries, and research suggests new medical technologies such as drugs, devices, diagnostics and surgical t...
متن کاملPhysician and enrollee knowledge of Medicaid coverage for tobacco dependence treatments.
BACKGROUND The 2000 Public Health Service Clinical Practice Guideline, Treating Tobacco Use and Dependence, recommends health insurance coverage for tobacco-dependence treatments proven effective in helping smokers to quit. Two states with comprehensive coverage for tobacco-dependence treatments in their Medicaid programs were selected to document awareness of coverage for tobacco-dependence tr...
متن کاملPro/Con debate: Should 24/7 in-house intensivist coverage be implemented?
You are appointed director of a new large multi-discipline intensive care unit in an academic center. The hospital is affiliated with a medical school and as such there will be an adequate number of medical students, residents, and fellows (specializing in critical care) rotating through the unit. The unit will be a 'closed' (intensivist-led) model. In setting up the call schedule for the inten...
متن کاملCardiac surgery in octogenarians and beyond.
Should we do it, is it worthwhile, and who should decide?
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Specialty law digest. Health care law
دوره 226 شماره
صفحات -
تاریخ انتشار 1997